Home › Funds › ARMISTICE CAPITAL, LLC › NKTR
ARMISTICE CAPITAL, LLC position in NKTR
NEKTAR THERAPEUTICS · Health Care
ARMISTICE CAPITAL, LLC reported holding 700,000 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$42.4M, representing 0.58% of its reported portfolio and ranking #20 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed NKTR holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ARMISTICE CAPITAL, LLC's NKTR position evolved
ARMISTICE CAPITAL, LLC first disclosed a stake in NKTR in Q2 2024 at 836,000 shares (US$1.0M). The position peaked in Q2 2026 at 724,000 shares, worth US$50.5M. Across 10 filings, ARMISTICE CAPITAL, LLC increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 700,000 shares valued at US$42.4M — a reduction of -24,000 shares quarter over quarter.. Notable position changes include a 88% trim in Q2 2025 (shares rose 120% over the following quarter), a 116% increase in Q3 2025 (shares fell 26% over the following quarter), a 122% increase in Q4 2025 (shares rose 70% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 836.00K | $1.04M | New |
| Q3 2024 | 1.00M | $1.30M | Add |
| Q4 2024 | 1.02M | $952.32K | Add |
| Q1 2025 | 1.04M | $704.48K | Add |
| Q2 2025 | 124.00K | $3.20M | Reduce |
| Q3 2025 | 268.00K | $15.25M | Add |
| Q4 2025 | 596.00K | $25.20M | Add |
| Q1 2026 | 578.00K | $41.59M | Reduce |
| Q2 2026 | 724.00K | $50.54M | Add |
| Q3 2026 | 700.00K | $42.38M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NKTR and 13F data
NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 56 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NKTR
- Two Seas Capital LP 3.35M sh · $202.58M · Q3 2026
- BVF INC/IL 2.39M sh · $166.92M · Q2 2026
- Vestal Point Capital, LP 1.00M sh · $69.81M · Q2 2026
- Prosight Management, LP 785.00K sh · $47.53M · Q3 2026
- BRAIDWELL LP 473.62K sh · $33.06M · Q2 2026
- ORBIMED ADVISORS LLC 465.35K sh · $32.49M · Q2 2026
- DAFNA Capital Management LLC 318.38K sh · $22.23M · Q2 2026
- 22NW, LP 281.12K sh · $17.02M · Q3 2026
- ADAR1 Capital Management, LLC 258.18K sh · $15.63M · Q3 2026
- SEVEN GRAND MANAGERS, LLC 240.00K sh · $14.53M · Q3 2026
- Bronte Capital Management Pty Ltd. 202.06K sh · $12.23M · Q3 2026
- GREAT POINT PARTNERS LLC 175.00K sh · $12.22M · Q2 2026
More on ARMISTICE CAPITAL, LLC
FAQ
How long has ARMISTICE CAPITAL, LLC held NKTR?
ARMISTICE CAPITAL, LLC has disclosed NKTR holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is ARMISTICE CAPITAL, LLC's current position in NKTR?
As of Q3 2026, ARMISTICE CAPITAL, LLC holds 700.00K shares of NKTR (NEKTAR THERAPEUTICS), valued at $42.38M, representing 0.58% of its reported portfolio and ranking #20.
Has ARMISTICE CAPITAL, LLC been buying or selling NKTR?
In the latest 13F filing (Q3 2026), ARMISTICE CAPITAL, LLC reduced its position in NKTR. The position peaked in Q2 2026 at 724.00K shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.